Basel scientists have confirmed that the malaria drug hydroxychloroquine and the HIV medication lopinavir do not work against Covid-19. The concentration of the two drugs in the lungs is not sufficient to fight the virus.
In February 2020 the University of Basel and the University Hospital Basel started to monitor a range of diagnostic means and potential treatments for Covid 19, including the use of hydroxychloroquine and lopinavir/ritonavir.
In particular, the research group investigated how the virus-induced inflammation affected the concentration of lopinavir and hydroxychloroquine in the blood.
Scientists also worked out how high the concentration of both drugs must have been in the lungs – the main infected area for Covid-19.
The study, which has been published in the Antimicrobial Agents and Chemotherapy journal, confirms the view taken by the World Health Organization (WHO). On July 4 it decided to discontinue trials of hydroxychloroquine and lopinavir/ritonavir in hospitalised patients with Covid-19 after the drugs failed to reduce mortality.
Manuel Battegay – co-leader of this study and head of the Division of Infectious Diseases and Hospital Epidemiology at the University Hospital in Basel – said that the results of the Basel study provided important pharmacological and antiviral insights to the rationale of discontinuing the lopinavir/ritonavir trials.
“In fact, they explain why hydroxychloroquine and lopinavir are not effective against the SARS-CoV-2,” the statement said.
Political debate
Hydroxychloroquine has been caught in a political debate after United States President Donald Trump promoted it, even though there was no scientific evidence that it helps against the new coronavirus.
Brazilian President Jair Bolsonaro, who on Tuesday announced that he had tested positive for Covid-19, said he was taking hydroxychloroquine. He has previously urged his government to make the malaria drug widely available and encouraged Brazilians to take it, both to prevent the disease and to treat it.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Switzerland invites 160 delegations to June Ukraine peace talks
This content was published on
Russia is currently not among the delegations invited to talks aimed at helping bring about peace in the conflict between Moscow and Ukraine.
Survey: air travel most popular way to go on holidays for Swiss
This content was published on
Despite the climate crisis, flying is the most popular mode of transport for private travel – particularly among young, urban and high-income travellers.
Swiss government to use phone data to identify asylum seekers
This content was published on
From April 2025, authorities plan to be able to analyse data from mobile phones, computers and other data carriers to identify asylum seekers.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis ends hydroxychloroquine clinical trial
This content was published on
Swiss drug giant Novartis is ending its trial of malaria drug hydroxychloroquine against Covid-19 after failing to find enough participants.
Hydroxychloroquine study withdrawn over data concerns
This content was published on
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.